Richard A. Paulson Karyopharm Therapeutics Inc. (KPTI) insider trading activity

Richard A. Paulson is President and CEO of Karyopharm Therapeutics Inc.. Currently has a direct ownership of 1.12 Million shares of KPTI, which is worth approximately $672,094. The most recent transaction as insider was on Feb 04, 2025, when has been sold 4,099 shares (Common Stock) at a price of $0.65 per share, resulting in proceeds of $2,664. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.12M

1.04% 3M change

36.36% 12M change

Total Value Held $672,094

Richard A. Paulson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 04 2025	SELL Open market or private sale	$2,664 $0.65 p/Share	4,099 Reduced 0.36%	1,120,158 Common Stock
Jan 06 2025	SELL Open market or private sale	$3,162 $0.78 p/Share	4,055 Reduced 0.36%	1,124,257 Common Stock
Dec 04 2024	SELL Open market or private sale	$2,932 $0.81 p/Share	3,620 Reduced 0.32%	1,128,312 Common Stock
Nov 05 2024	SELL Open market or private sale	$3,344 $0.91 p/Share	3,675 Reduced 0.32%	1,131,932 Common Stock
Oct 04 2024	SELL Open market or private sale	$3,174 $0.88 p/Share	3,607 Reduced 0.32%	1,135,607 Common Stock
Sep 04 2024	SELL Open market or private sale	$2,640 $0.72 p/Share	3,667 Reduced 0.32%	1,139,214 Common Stock
Aug 06 2024	SELL Open market or private sale	$3,355 $0.93 p/Share	3,608 Reduced 0.31%	1,142,881 Common Stock
Jul 05 2024	SELL Open market or private sale	$3,073 $0.85 p/Share	3,616 Reduced 0.31%	1,146,489 Common Stock
Jun 04 2024	SELL Open market or private sale	$3,556 $0.99 p/Share	3,592 Reduced 0.31%	1,150,105 Common Stock
May 06 2024	SELL Open market or private sale	$4,040 $1.13 p/Share	3,576 Reduced 0.31%	1,153,697 Common Stock
Apr 04 2024	SELL Open market or private sale	$4,596 $1.29 p/Share	3,563 Reduced 0.31%	1,157,273 Common Stock
Mar 05 2024	SELL Open market or private sale	$4,644 $1.3 p/Share	3,573 Reduced 0.31%	1,160,836 Common Stock
Mar 01 2024	SELL Open market or private sale	$23,248 $1.2 p/Share	19,374 Reduced 1.64%	1,164,409 Common
Feb 29 2024	SELL Open market or private sale	$94,149 $1.17 p/Share	80,470 Reduced 6.37%	1,183,783 Common
Feb 28 2024	BUY Grant, award, or other acquisition	-	442,800 Added 25.94%	1,264,253 Common Stock
Feb 06 2024	SELL Open market or private sale	$6,379 $1.59 p/Share	4,012 Reduced 0.49%	821,453 Common Stock
Jan 24 2024	BUY Grant, award, or other acquisition	-	42,000 Added 4.84%	825,465 Common Stock
Jan 04 2024	SELL Open market or private sale	$3,373 $0.82 p/Share	4,114 Reduced 0.52%	783,465 Common Stock
Dec 04 2023	SELL Open market or private sale	$2,861 $0.79 p/Share	3,622 Reduced 0.46%	787,579 Common Stock
Nov 06 2023	SELL Open market or private sale	$3,317 $0.92 p/Share	3,606 Reduced 0.45%	791,201 Common Stock
Oct 04 2023	SELL Open market or private sale	$4,558 $1.27 p/Share	3,589 Reduced 0.45%	794,807 Common Stock
Sep 05 2023	SELL Open market or private sale	$4,817 $1.33 p/Share	3,622 Reduced 0.45%	798,396 Common Stock
Aug 07 2023	SELL Open market or private sale	$6,401 $1.72 p/Share	3,722 Reduced 0.46%	802,018 Common Stock
Jul 05 2023	SELL Open market or private sale	$6,085 $1.72 p/Share	3,538 Reduced 0.44%	805,740 Common Stock
Jun 05 2023	SELL Open market or private sale	$7,920 $2.24 p/Share	3,536 Reduced 0.44%	809,278 Common Stock

Also insider at

BLUE

bluebird bio, Inc. Healthcare

RAP